02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
23:04 , Mar 7, 2017 |  BC Week In Review  |  Company News

AZ, Sanofi deal

The MedImmune LLC unit of AstraZeneca and Sanofi’s Sanofi Pasteur vaccines unit partnered to develop and commercialize MedImmune's MEDI8897 . AZ will continue development of MEDI8897 until its first approval and is responsible for manufacturing....
17:43 , Mar 3, 2017 |  BC Extra  |  Company News

AZ, Sanofi sharing rights to infant RSV prophylaxis

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) and the Sanofi Pasteur vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) said they will share rights to develop and commercialize infant respiratory syncytial virus (RSV) therapeutic MEDI8897...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

RSV mAb regulatory update

AstraZeneca’s MedImmune LLC unit said FDA granted Fast Track designation to MEDI8897 to prevent lower respiratory tract infection caused by respiratory syncytial virus (RSV) in infants and young children. The human IgG1 kappa mAb against...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Fused bispecific antibodies

Drug platforms TECHNOLOGY: Antibody scaffolds Cell culture and mouse studies suggest chemical and enzymatic coupling of two full-sized blocking antibodies at their carboxy termini could produce bispecific molecules that retain full activity against both targets....
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Allovectin velimogene aliplasmid: Additional Phase III data

Additional data from the single-blind, international Phase III AIMM trial in 390 chemotherapy-naïve patients with recurrent stage III or IV metastatic melanoma showed that 2 mg intralesional Allovectin led to an ORR at >=24 weeks,...
08:00 , Nov 14, 2013 |  BC Innovations  |  Targets & Mechanisms

RSVing for site zero

Despite decades of research, respiratory syncytial virus (RSV) remains a highly prevalent childhood pathogen without an approved vaccine. 1 There is a marketed prophylactic- Synagis palivizumab-to prevent severe disease caused by RSV in at-risk infants,...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Vical cancer, infectious news

Vical will reduce headcount by 47 (39%) to about 74. The cuts include Alain Rolland, who departed as EVP of product development. Last month, the biotech discontinued development of Allovectin velimogene aliplasmid after top-line data...